{"groups":[{"description":"Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO\n\nVorinostat: Given PO","id":"FG000","title":"Arm I (Capecitabine, Vorinostat)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}